Mobile

A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide fo...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-003134-14

A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with interferon-beta in subjects with multiple sclerosis

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To investigate the tolerability and safety of a 7 mg and a 14 mg dose of teriflunomide administered once daily for 24 weeks, compared with placebo in subjects with multiple sclerosis who are concurrently on a stable dose of interferon-beta

Critère d'inclusion

  • Multiple sclerosis

Liens